key: cord-0755058-23mikqfz authors: Pearson, Sara Catherine; O’Connor, Kristin; Keller, Kimberly; Hodge, T J; Nesbit, Ross title: Efficacy of standard- vs reduced-dose insulin for treatment of hyperkalemia: A quasi-experiment date: 2021-10-01 journal: Am J Health Syst Pharm DOI: 10.1093/ajhp/zxab382 sha: 9cde9859827dfa0fb1c6b1d4b478534ed4993b9f doc_id: 755058 cord_uid: 23mikqfz DISCLAIMER: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE: Hyperkalemia more commonly affects patients with a glomerular filtration rate of less than 60 mL/min. Using intravenous (IV) insulin to shift potassium intracellularly may cause hypoglycemia, requiring additional treatment or longer hospitalization. Literature on insulin dosing in this context is limited, with one previous study indicating that 5 units of IV insulin might be as effective and result in less hypoglycemia than the standard dose of 10 units of IV insulin. The hyperkalemia treatment pathway at our institution was revised in May 2018 to include a reduced-dose option (5 units of insulin) for patients with end-stage renal disease. This study aimed to compare the prevalence of hypoglycemia between patients who received standard-dose vs reduced-dose IV insulin. METHODS: This single-center, retrospective, quasi-experimental study evaluated the impact of revision of the hyperkalemia treatment pathway by assessing rates of hypoglycemia during the 6 months before and after implementation of the revised pathway. The primary endpoint was prevalence of hypoglycemia, defined as a blood glucose level of less than or equal to 70 mg/dL. RESULTS: There was no statistically significant difference in the occurrence of hypoglycemia when comparing the pre- and postimplementation groups (36 [17.7%] patients vs 34 [18.7%] patients; P = 0.7924). The postimplementation group had a statistically significant lower reduction in potassium levels after treatment than the preimplementation group (mean [interquartile range], –0.9 [–1.3, –0.5] mEq/L vs –0.6 [–1.2, –0.2] mEq/L; P = 0.0095). Baseline potassium levels were similar between the groups. CONCLUSION: Administration of reduced-dose IV insulin for treatment of hyperkalemia was significantly less effective in lowering serum potassium levels and did not decrease prevalence of hypoglycemia. When accounting for potential confounders, the only variable that was associated with hypoglycemia was pretreatment glucose level. M a n u s c r i p t The incidence of acute hyperkalemia in hospitalized patients is well documented in the literature, occurring in 1% to 10% of patients. 1 Hyperkalemia disproportionately affects hospitalized patients with renal dysfunction, more commonly occurring in patients with a glomerular filtration rate (GFR) of less than 60 mL/min. [2] [3] [4] [5] [6] [7] Treatment options for hyperkalemia consist of calcium gluconate, intravenous (IV) insulin, loop diuretics, albuterol, and potassium binders. 8, 9 Although hemodialysis is the most effective method for removing potassium in a patient with end-stage renal disease (ESRD), this may not be a readily available option depending on hospital resources. Use of IV insulin can effectively shift potassium into the intracellular space, but this carries the risk of hypoglycemia. 9, 10 Insulin's propensity to cause hypoglycemia, cited in the literature as occurring at a rate of 6% to 20%, may warrant additional treatment and potentially prolong the hospital stay. [11] [12] [13] Patients with renal impairment are thought to be more susceptible to hypoglycemia owing to a reduced capacity to break down insulin. 12 Theoretically, patients with renal dysfunction may require reduced doses of IV insulin for the management of hyperkalemia, but data in support of this are limited. Several small studies have demonstrated that 5 units may be equally as effective as 10 units in reducing hyperkalemia while minimizing incidence of hypoglycemia. [9] [10] [11] [12] Garcia Because of concern regarding high prevalence of hypoglycemia in treatment of hyperkalemia, a multidisciplinary team was convened in the spring of 2018 to review and revise the emergent hyperkalemia treatment pathway at our institution. This pathway is available for all providers to use through computerized physician order entry and includes laboratory tests, diagnostic tests such as electrocardiography (ECG), and pharmacological treatments for hyperkalemia. The multidisciplinary team decided that there were 2 major changes that could be made in an effort to reduce the incidence of hypoglycemia. The first change was to increase the upper glucose limit at which dextrose would be administered before administration of IV insulin. Previously, the upper limit to administer dextrose was 200 mg/dL. As part of the pathway revision, this limit was raised to 250 mg/dL, increasing the number of patients who would receive dextrose before IV administration of insulin. The second major change was creation of an ESRD subphase that defaulted insulin dosing to 5 units and a non-ESRD subphase that defaulted insulin dosing to 10 units. Previously, all patients received 10 units of IV insulin via this pathway. The revisions to the emergent hyperkalemia treatment pathway were implemented in May 2018. The aim of this study was to evaluate the impact of these changes on the prevalence of hypoglycemia and reduction in potassium levels for all patients for whom this pathway was ordered and further add to the literature surrounding efficacy of reduceddose insulin in hyperkalemia treatment. A c c e p t e d M a n u s c r i p t Methods Patient population. This was a single-center, retrospective, quasi-experimental study evaluating the impact of a revised hyperkalemia treatment pathway on the rate of hypoglycemia, defined as a blood glucose level of less than or equal to 70 mg/dL, at an academic medical center in the southeastern United States. Less than or equal to 70 mg/dL was chosen as the breakpoint for hypoglycemia because this is the number used at our institution to define hypoglycemia and reflects the definition established by the American Diabetes Association. Revisions to the emergent hyperkalemia treatment pathway were implemented at our institution on May 28, 2019. Data were collected for patients who received IV insulin via this pathway in the 6 months before pathway revision and the 6 months after pathway revision for a total of 12 months of data from November 28, 2018, to November 28, 2019. This study was approved by the institutional review board at our institution. Patients were excluded if they did not receive IV insulin as part of the emergent hyperkalemia treatment pathway, did not have follow-up glucose and potassium levels documented within 6 hours of pathway initiation, or had received IV insulin within the previous 48 hours. Patients were identified by a pathway compliance marker that pulled all available patients for whom the hyperkalemia pathway was ordered within the study period. This method identified a total of 710 patients to be screened for inclusion. Of these patients, 204 patients were included in the preimplementation group and 182 patients were included in the postimplementation group. The reasons for exclusion are shown in Figure 1 . The primary endpoint was prevalence of hypoglycemia. The secondary endpoints were length of stay and potassium level 6 hours after insulin administration. A c c e p t e d M a n u s c r i p t Study design and methods. We investigated the difference in outcomes following revisions to the emergent hyperkalemia treatment pathway at our institution. Before revision, the pathway included orders for calcium gluconate 1,000 mg, insulin 10 units IV, sodium bicarbonate IV 50 mEq, 50% dextrose 25 g, and oral sodium polystyrene sulfonate (SPS). The threshold for administering dextrose before insulin was 200 mg/dL. After revision, the pathway included the same drug therapy, except it excluded sodium bicarbonate and oral SPS. Sodium bicarbonate was excluded because of conflicting evidence in the literature. SPS was changed to administration per rectum only owing to the need for faster onset of action. The threshold for administering dextrose before insulin was increased to 250 mg/dL, meaning that patients with higher glucose levels would now receive dextrose when they previously would not have. Additionally, the revised pathway included 2 subphases: a non-ESRD treatment subphase and an ESRD treatment subphase. The non-ESRD subphase included a default IV insulin dose of 10 units while the ESRD treatment subphase included a default IV insulin dose of 5 units. Data were collected from the electronic medical record (EMR) and included demographic information, history of diabetes and/or ESRD, serum creatinine levels, potassium levels, glucose levels, timing of administration of medications, drugs commonly administered via the hyperkalemia pathway (ie, dextrose, sodium bicarbonate, inhaled albuterol, and SPS), length of stay, ECG changes, medications with the propensity to contribute to hyperkalemia (ie, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, nonsteroidal anti-inflammatory drugs, and sulfamethoxazole/trimethoprim), medications with the ability to affect glucose levels (ie, dextrose-containing continuous fluids and/or IV piggybacks, oral or IV steroids, fluoroquinolone antibiotics, and oral antidiabetic A c c e p t e d M a n u s c r i p t agents), and comorbid conditions to calculate the Charlson Comorbidity Index (CCI). These data are shown in Tables 1-4 . On the basis of the available literature, we expected an effect size of 10%, correlating to an event rate of 20% in the preimplementation group and 10% in the postimplementation group. 11,12 Using a 2-tailed hypothesis, an alpha value of 0.05, a beta value of 0.20, and an equal allocation rate to the treatment arms, 199 participants were predicted to be required in each group to meet power, for a total sample size of 398. Institute, Cary, NC). All continuous variables were evaluated for normality using a Shapiro-Wilk test, a Kolmogorov-Smirnov test, and visual inspection of histograms. None of the continuous variables were found to have a normal distribution; thus, all between-group comparisons were performed with the Mann-Whitney U test. Continuous variable results are presented as median and interquartile range. Between-group comparisons of categorical variables were evaluated using a  2 or Fisher's exact test, as appropriate. The null hypothesis of no difference was rejected if the between-group comparison P value was less than 0.05. We identified 710 patients for whom the emergent hyperkalemia treatment pathway was ordered during the study period. A total of 324 patients were excluded. The primary reason for exclusion was absence of repeat glucose and/or potassium values after insulin administration (n = 170, 52%) ( Figure 1 ). A total of 386 patients met the inclusion criteria, with M a n u s c r i p t 204 patients in the preimplementation group and 182 patients in the postimplementation group for analysis. Patient demographics were well balanced between the groups (Table 1) , and use of medications that may contribute to hyperkalemia was the only statistically significant difference (Table 3) In this study, we investigated the difference in outcomes following revisions to the emergent hyperkalemia treatment pathway at our institution. Despite changes to this pathway, we found no difference in the prevalence of hypoglycemia between patient groups. The multivariable regression analysis performed demonstrated that, for every 1 mg/dL decrease in the baseline glucose level, the odds of developing hypoglycemia were 0.987 when all other variables were controlled. This led us to hypothesize that patients with lower baseline glucose levels may benefit from receipt of a higher amount of dextrose, 50 g instead of the current A c c e p t e d M a n u s c r i p t standard of 25 g, before IV insulin administration. In the future, we may implement a dextrose scale in which 50 g is administered for blood glucose levels below 150 mg/dL, 25 g is administered for blood glucose levels of 150 to 250 mg/dL, and 12.5 g is administered for blood glucose levels of 251 to 300 mg/dL. Additionally, we found that use of 5 units of IV insulin was less effective than use of 10 units in regard to reduction of serum potassium levels. It is important to note that changes to the pathway resulted in significantly lower utilization of IV sodium bicarbonate and oral SPS. Although these agents lack robust evidence for efficacy in treatment of hyperkalemia, the between-group differences in use of these agents may have been a confounding factor in our results. We also note that the onset of action of SPS, when given rectally, is 1 to 2 hours, whereas that for patiromer is 6 to 7 hours. 16 In the acute treatment setting, we feel that the difference in reduction of potassium levels between groups could be a significant finding. Inadequate potassium reduction may require additional treatment and may increase the risk of adverse outcomes from additional treatment or prolonged time before resolution of hyperkalemia. Even when accounting for patients with ESRD, the potassium reduction was significantly less in patients who received less than 10 units of IV insulin. This study was inherently limited by the inability to control for external factors. The retrospective nature of this study precluded the ability to control for variables such as timely laboratory draws or recording of medication administration. Serum potassium levels were collected at the time point nearest insulin administration if this was within 6 hours, but many patients were excluded because they did not have follow-up laboratory results recorded within A c c e p t e d M a n u s c r i p t this time window. We feel that, although there are many factors that may contribute to this delay, there is significant room for improvement in this area. In a controlled clinical setting, all patients who received this treatment pathway would have follow-up laboratory testing. Multiple factors may have contributed to missing laboratory results, including patients transferring floors, patients leaving the floor for imaging or dialysis, or hemolysis of samples. Additionally, providers can order select items and modify orders within the treatment pathway. Although our aim was to compare the outcomes of the original and revised pathways, providers' clinical decision-making would impact whether a patient received the treatment pathway as it was built or received a modified version of the pathway, which could impact results. For patients without documented ESRD in the EMR, we were unable to determine whether their renal impairment was acute or chronic in nature. Related to this, we also were unable to identify the chronicity of hyperkalemia or quantify how often or recently a patient might have received treatment for hyperkalemia. Our hypoglycemia results are reported as any patient with glucose levels less than or equal to 70 mg/dL; however, our institutional policy states that the first treatment that nurses should provide to patients is 4 ounces of orange juice, which is often not easily viewable in the EMR. Administering orange juice would provide an additional 3.3 mEq of potassium to a patient who is already hyperkalemic. Unfortunately, we were not able to collect this information on patients or control for this confounding factor. We tracked patients who required IV dextrose for hypoglycemia and were able to quantify how much dextrose they required for treatment; however, we were not able to quantify how often nonpharmacological treatment was utilized for patients with hypoglycemia.  Changes in the hyperkalemia treatment pathway were implemented to reduce the incidence of hypoglycemia, including a reduced insulin dose (5 units) and a higher threshold for administering dextrose before insulin.  Np significant change was found in the prevalence of hypoglycemia, although patients who experienced hypoglycemia tended to have a lower pretreatment blood glucose level than patients who did not. A c c e p t e d M a n u s c r i p t Dextrose-containing fluids were defined as receipt of any intravenous fluids containing dextrose, ie, intravenous antibiotics diluted in dextrose or 5% dextrose in water as a continuous fluid. M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Reduced versus conventional dose insulin for hyperkalemia treatment Incidence of hypoglycemia in patients with low eGFR treated with insulin and dextrose for hyperkalemia Incidence of hypoglycemia following insulinbased acute stabilization of hyperkalemia treatment Treatment of hyperkalemia with a low-dose insulin protocol is effective and results in reduced hypoglycemia Hypoglycemia following intravenous insulin plus glucose for hyperkalemia in patients with impaired renal function A comparison of insulin doses for the treatment of hyperkalemia in patients with renal insufficiency The authors would like to acknowledge A. Shaun Rowe, PharmD, for providing statistical analysis and support and Christopher Johns, BS, for his assistance with data collection. The authors have declared no potential conflicts of interest. A c c e p t e d M a n u s c r i p t Tennessee Medical Center.